Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07823270) titled 'Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Hebei Medical University Fourth Hospital
Condition:
Esophageal Squamous Cell Carcinoma
Intervention:
Drug: Sacituzumab tirumotecan
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 2026
Target Sample Size: 33
Countries of Recruitment:
China
To know more, visit https://clinic...